Obinutuzumab‐related adverse events: A systematic review and meta‐analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Obinutuzumab‐related adverse events: A systematic review and meta‐analysis
Authors
Keywords
-
Journal
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-11-30
DOI
10.1002/hon.2828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
- (2020) Lydia Scarfò et al. LEUKEMIA
- Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: What do we know after 20 years of rituximab
- (2019) Daniele Focosi et al. REVIEWS IN MEDICAL VIROLOGY
- A tale of two antibodies: obinutuzumab versus rituximab
- (2018) Ciara L. Freeman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
- (2018) Wolfgang Hiddemann et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
- (2017) Umberto Vitolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is watch and wait still acceptable for patients with low-grade follicular lymphoma?
- (2016) J. O. Armitage et al. BLOOD
- Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12
- (2016) H S Walter et al. Blood Cancer Journal
- Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
- (2015) C. L. Freeman et al. BLOOD
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
- (2015) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
- (2015) V Goede et al. LEUKEMIA
- Suboptimal dosing of rituximab in male and female patients with DLBCL
- (2013) M. Pfreundschuh et al. BLOOD
- Rituximab resistance
- (2011) Andrew R. Rezvani et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
- (2011) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
- (2011) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma
- (2009) David Ternant et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
- (2008) Robert Marcus et al. JOURNAL OF CLINICAL ONCOLOGY
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now